Nevro (NYSE:NVRO) Corp, headquartered in Redwood City, California, is a global medical device company specializing in neuromodulation therapy for chronic pain management. Founded in 2006, Nevro has pioneered the development of high-frequency spinal cord stimulation (SCS) technology designed to deliver long-lasting pain relief without the paresthesia commonly associated with traditional SCS systems. The company’s innovative approach has earned it a prominent position in the field of interventional pain medicine.
The cornerstone of Nevro’s portfolio is the Senza® System, featuring its proprietary HF10® Therapy, which operates at 10 kHz to target pain signals in the spinal cord. In addition, the company’s Evoke® SCS System incorporates closed-loop feedback through ECAP (evoked compound action potential) sensing, allowing personalized adjustments to stimulation in real time. Nevro’s devices are indicated for the treatment of chronic intractable pain of the trunk and/or limbs, and they are supported by an extensive body of clinical evidence demonstrating sustained pain reduction and improved patient quality of life.
Nevro’s products are marketed across North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific region. The company maintains a direct sales force in key markets, complemented by strategic partnerships and distribution agreements in select countries. Nevro also invests in comprehensive physician training programs and patient support services to ensure optimal therapy outcomes and foster long-term adoption of its technologies.
Under the leadership of President and Chief Executive Officer Arjun Sinha and an experienced senior management team, Nevro continues to advance its research and development efforts. The company’s commitment to innovation is reflected in ongoing clinical studies, regulatory submissions, and collaborations with academic and medical institutions worldwide. By focusing on evidence-based solutions and patient-centric initiatives, Nevro aims to further expand access to its high-frequency neuromodulation therapies for individuals living with chronic pain.
